Shortcut to success? : Negotiating genetic uniqueness in global biomedicine by Tarkkala, Heta & Tupasela, Aaro
FINAL DRAFT, ACCEPTED FOR PUBLICATION IN SOCIAL STUDIES OF SCIENCE (Vol 
48, Issue 5, 2018)
Shortcut to success? Negotiating genetic uniqueness in global biomedicine
Heta Tarkkala
Department of Social Sciences, University of Eastern Finland, Finland
Faculty of Social Sciences, University of Helsinki, Finland
Aaro Tupasela
Section of Health Services Research, Department of Public Health, University of Copenhagen, 
Denmark
Abstract
Since the sequencing of the human genome, as well as the completion of the first Human Genome 
Diversity Project, the benefits of studying one human population over another has been an ongoing 
debate relating to the replicability of findings in other populations. The leveraging of specific 
populations into research markets has made headlines in cases such as deCode in Iceland, Quebec 
Founder Population, and Generation Scotland. In such cases, researchers and policy makers have 
used the genetic and historical uniqueness of their populations to attract scientific, commercial and 
political interest. In this article, we explore how in countries with population isolates, such as 
Finland, the researchers balance considerations relating to the generalization and replicability of 
findings in small yet unique research populations to global biomedical research interests. This 
highlights challenges related to forms of competition associated with genetics research markets, as 
well as what counts as the ‘right’ population for genetic research.
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Introduction
After the initial sequencing of the first human genome (International Human Genome Sequencing 
Consortium, 2001) and the development of high-throughput sequencing, it became increasingly 
possible and inexpensive to capture the genetic variation that was present among human 
populations around the world (Gannett, 2001). Initiatives included such sequencing projects as the 
1000 Genomes project (Birney and Soranzo, 2015), the 100 000 genomes project in the UK and the 
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All of Us Research Program in the US.1 New analytical approaches, such as Genome Wide 
Association Studies (GWAS), were important in identifying variants associated with disease and 
other traits, generating a narrative of quickly identifying disease-causing variations. One of the 
challenges, which emerged out of these new technical and methodological possibilities, was 
identifying those populations that researchers considered representative enough to make replicable 
generalizations across human populations, while at the same time being competitive in terms of 
price and speed of delivery. In this article, we explore how researchers and biobank experts in small
countries, such as Finland, seek to balance considerations relating to the generalization and 
replicability of findings in small, yet unique, research populations to global biomedical research 
interests. These efforts seek to generate both scientific interest, as well as economic investment. 
This discussion contributes to studies, which focus on the processes through which human tissue 
samples and related health information are made productive within global biomedical research 
markets (cf. Parry, 2004; Sunder Rajan, 2006; Waldby and Mitchell, 2006).
 
The Nordic countries have been consistently described by policy makers and medical researchers as
a ‘gold mine’ for genetic research (Nordforsk, 2014; Palotie et al., 2000), due to their high-quality 
biobanks, extensive population registers and lenient informed consent practices (Soini, 2013). Frank
(2000) has even suggested that the Nordic countries are cohorts in which the whole nation serves as 
the study population. Perhaps the best-known example of this has been deCode, with its interest in 
studying the Icelandic population (Fortun 2008; Pálsson 2007; Rose, 2001, 2003), but a number of 
other small population examples exist, such as the Faroe and Orkney Islands (Jorgensen et al., 2004;
Zara, 2015). In this context, most Nordic countries have sought to market and brand their 
populations as being unique and useful for biomedical research (Tupasela, 2017; Tupasela and 
Tamminen, 2015). Countries such as Finland (Tupasela et al., 2015) and Iceland (Rose, 2003) draw 
on narratives of homogeneity to position themselves as competitors in the global biomedical 
research market. Initiatives in other countries, such as Mexico (Kent et al., 2015: 846), India 
(Sunder Rajan, 2006: 165), Brazil (Gibbon, 2013), Singapore (Ong, 2016) and Estonia (Fletcher, 
2004), have drawn on historico-cultural narratives of national genetic heterogeneity to brand 
themselves as ideal targeted populations for medical research. 
It is important to note, however, that these efforts have drawn on a strong policy narrative of market
imaginaries of biobanks and populations as a new type of market resource. Experience has shown, 
however, that the marketization of populations is not as straightforward as originally thought. 
DeCode, for example, despite being referenced as an example of the marketization of the Icelandic 
population, has gone through multiple bankruptcies and been repeatedly re-sold to new owners (see 
also Aarden, 2017 on the Singapore Tissue Network). Similarly, the biobanking community has 
become increasingly concerned and interested in the long-term sustainability of their activities 
given the difficulties they have had in attracting investment and recouping expenses from services 
(Aarden, 2017; Vaught et al., 2011). Biobank bankruptcies and solvency problems have become an 
important concern for biobankers in general (Tupasela and Stephens, 2013). These challenges, 
however, have not stifled national attempts to make biobanks and populations attractive for 
international research collaboration, as well as investment.
 
In addition to the aforementioned national contexts, geneticists have sought to draw on unique 
population isolates to study diseases. Researchers have suggested that population isolates such as 
the Amish, Hutterites, Mennonite and Pima Indians (Varilo and Peltonen, 2004) are unique 
populations, which can be used to study disease-causing genes using smaller sample sizes because 
of their perceived homogeneity. Population isolates have been argued to confer specific advantages 
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in studying disease because the populations are seen to live in more uniform environments, have 
better genealogical and clinical records, have reduced genetic variability, and can have an 
enrichment of some phenotypes and diseases (Zara, 2015: 110). These arguments, however, 
invariably raise questions about what constitutes homogeneity, isolate populations and uniqueness, 
which would confer some type of research advantage over other populations. As Krieger (2012: 
634) has noted, ‘who and what makes a population has everything to do with whether population 
means are meaningful or meaningless, with profound implications for work on population health 
and health inequalities’. The valorization of both heterogeneous and homogenous populations as 
ideal types for medical research is an important phenomenon in that both rely on reified notions of 
population and population history.
 
Discussions within pharmacogenetics and genetics have introduced new forms of debates about the 
‘right’ type of population for medical research (cf. Epstein, 2007). In their study of 
pharmacogenomics in Brazil, for example, Ventura Santos et al. (2015: 48) have argued that there is
an ongoing valorization of race mixture or genomic heterogeneity as a resource for translational 
genetic research by Brazilian geneticists. Fujimura and Rajagopalan (2011) have argued that in their
attempts to avoid categories of race in their analyses, many researchers produce simultaneously 
different kinds of populations, as well as population differences. Likewise, Shim et al. (2014: 581) 
show that researchers ‘produce homogeneity along some dimensions and heterogeneity along others
in their study populations’, and thus that these concepts are situational, not inherent in their study 
populations. Furthermore, in thinking about the emergent field of niche marketing within 
pharmacogenomics (Epstein, 2007) it has become apparent that policy makers (as opposed just 
geneticists) may seek to position national or regional populations so as to attract a broader research 
interest in their populations (Tupasela, 2017). Indeed, many countries develop research markets 
based on their populations and the concomitant data (Hoeyer, 2016). Simultaneously contemporary 
biomedical research is increasingly becoming data-intensive, requiring large samples in order to 
gain statistical significance. By using vast sample and data collections, researchers hope to produce 
meaningful results about complex multi-variant diseases with methods such as GWAS (see i.e. 
Visscher et al., 2012). What countries such as Finland seek to market, however, is the ability to gain
statistical significance of finding disease-causing genes, by being able to use fewer samples than 
other population collections use.
In this article, we explore how geneticists in Finland negotiate the genetic uniqueness of the Finnish
population in order to attract international research funding and partners, while at the same time 
being able to make claims of easier and quicker paths to identifying disease causing genes. This 
requires convincing collaborators of the usability and replicability of findings in small populations 
for further studies in larger populations. At the same time, these very same populations should ‘fit 
in’ into large collaborative research projects that require data serving high-level research goals. 
We are interested in this connecting of potentials to populations for several reasons. First, the term 
‘unique’ population appears to refer to complementary virtues in genetics; arguments for the 
benefits and drawbacks of both homo- and heterogeneous populations appear to draw on the similar
set of arguments to generate meaningful results. Second, there is an ongoing debate among the 
biomedical research community as to which types of populations are best suited for studying 
disease causality and pharmacogenetic outcomes (Montoya, 2011; Weiss and Terwilliger, 2000); 
different actors argue in favor of heterogeneous or homogeneous populations. In countries such as 
Finland and Iceland, small populations with less variation are seen as a shortcut to success and a 
competitive advantage over heterogeneous populations where identifying genetic markers may 
require larger and more expensive sample sizes (Zara, 2015). Third, the discussions surrounding 
3
genetic uniqueness and homogeneity are closely related to questions of inclusion and identity, by 
which we mean that population characterizations rely heavily on developing selection criteria 
(Lipphardt, 2010; Prainsack, 2007: 85). For instance, in Taiwan the claim of the unique population 
requires balancing between the four main ethnic groups – groups that Tsai (2010) shows to be more 
hybrid and open to contestation than the practices of a population biobank in Taiwan would suggest.
In Singapore, the uniqueness and claimed potential usefulness of the collection in Biopolis comes 
from the claim that it represents all of ‘Asia’ (Ong, 2016). Finally, as populations become an 
interest for national marketing and innovation policy, their potentiality in scientific use becomes 
increasingly framed according to the demands of market forces, as well as driven by what nations 
consider their market niches. This may run counter to the interests of the research community and 
generate tensions among competing scientific programs, which in turn produces a need for further 
negotiations between scientists (both commercial and academic) and policy makers as to the 
purposes of national collections. 
 
Material and methods
 
Our general interest in studying unique populations, such as population isolates, stems from two 
interrelated research trajectories. The trajectory undertaken by Tarkkala has had its roots in a PhD 
research project on sample quality discussions and debates within the global biobank community, 
and their alignment for sample use with clinics, industry and university research. The second 
trajectory, which Tupasela has been pursuing in his research, relates to the marketization of 
population samples and its relations to the construction of national narratives of identity and 
sovereignty (cf. Tupasela, 2016). In combining these two perspectives, we began by examining 
international cases in which notions of homogeneity and heterogeneity have been deployed as 
arguments for what constitutes ‘good’ samples and collections for biomedical research. In this 
article, we focus on one particular substantiation of this debate using Finland as a case, but relating 
it to other similar cases found globally. 
Our broader data set consists of official documents, newspaper articles, and scientific articles from a
number of international cases – Mexico (Benjamin, 2009), Brazil (Gibbon, 2016; 2013), Quebec 
(Hinterberger, 2012), Iceland (Pálsson, 2007), Singapore (Ong, 2016), Taiwan (Tsai, 2010), and 
Finland (Tupasela et al., 2015) – where these debates have taken place and which have received 
social scientific or anthropological research attention. We have sought to use these cases to identify 
the key dynamics in the debate between the benefits of one type of population over another (homo- 
and heterogeneity), as well as the ways in which these categories are constructed. In addition to 
documents and articles, we draw on the specific case of Finland, where we have collected and 
analyzed official documents, public scientific presentations, newspaper articles, radio interviews, 
field notes and scientific articles. 
 
We have conducted almost 50 semi-structured interviews with informants in Finland between 2011 
and 2016. The informants we interviewed worked in establishing biobanks, mainly in Finland, in 
different ways: they were researchers, clinicians or worked for the biobanks. Some key informants 
were interviewed two or even three times and in some interviews multiple informants were present. 
The field notes were based on public presentations held on the topic, as well as site visits. We 
collected these materials as they came by and whenever there was an opportunity to participate in 
such events and conferences.2 
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In order to understand the significance that discussions surrounding homogeneity and heterogeneity 
in the Finnish population, it is necessary to recognize the history of medical research in Finland and 
its relationship to historico-cultural notions of Finnishness (Tupasela, 2015). Appiah (2005: 151) 
has noted that ‘upholding differences among groups may entail imposing uniformity among them’. 
Such processes of imposing uniformity among groups may create new categories whose relevance 
in international research markets may not be clear. The construction of difference in a medical sense
began in Finland in the 1960s, with a number of studies examining what has been termed the 
Finnish population ‘structure’. HR Nevanlinna (1922-1994), who was one of Finland’s foremost 
medical experts in population genetics, notes in an early study into Finnish population structure, 
where ethnic groups were understood and studied in relation to whether they spoke Finnish or 
Swedish: ‘In order to avoid contamination among these and some smaller ethnic groups as well, the 
sampling was made from the rural population only’ (Nevanlinna, 1972: 195). The search for 
polymorphic and rare marker genes in the Finnish population was, therefore, from the outset based 
on identifying and studying families and population isolates (‘super isolates’). Over several 
generations, these super isolates gave rise to the enrichment of particular disease genes and 
polymorphisms, which were used to ‘illustrate the peculiar structure of the Finnish rural population’
(Nevanlinna, 1972: 196). Similar studies conducted during the same time, such as on congenital 
nephrosis (Norio, 1966), also provided important insights into the ways in which heredity and 
inbreeding in small communities – which researchers later described as a homogenous population –
contribute to such peculiarities. Already at this early stage, there was an interest to make 
delineations as to which groups of people could be included and excluded from the study samples. 
 
These genetic peculiarities, however, also came at a price. Since many of the genetic variations 
were unique to the Finnish population, the ability to extrapolate and generalize about them to other 
populations was also a challenge. Although the notion of homogeneity made it easier to find gene 
variants in smaller sample populations, it also raised the issue of whether this was something unique
to Finland. Finnish researchers were concerned about whether this was of any interest to the 
international research community or nothing more than a local curiosity, which did not have 
actionable medical significance for others. With the recent increased internationalization of 
biomedical research and the increased policy pressure to make national collections visible and 
matter globally, there has been an interest in highlighting the usability of these collections (Ministry
of Social Affairs and Health, 2015; see also Ministry of Health, 2017 for a Danish example). We 
see these negotiations as providing important insights into the increased intertwining of market 
demands and scientific considerations in global biomedical research.
Intertwined scientific and commercial markets are central to our account. Scientific markets 
concern the academic prestige and visibility provided by international scientific publications, as 
well as by claims to discovery and knowledge of unique diseases (Tupasela, 2016). Commercial 
markets center on the ability to attract private partners, in the form of pharmaceutical and diagnostic
companies to partner with and invest money in Finnish research groups. The two cannot be neatly 
separated, but rather re-enforce the authority of the other, as can be seen in the case of deCode. 
 
In the following, we first discuss how research markets are emerging within global biobanking. 
Then we discuss this phenomenon in the case of Finland, relating it to the fluidity of categories of 
homogeneity and heterogeneity. Finally, we will discuss the further connections of these categories 
to the scientific production of knowledge more generally.
Constructing markets for genetics research
5
In this paper we explore a particular type of genetic research market, representing a small fraction 
of the types of markets that exist for human tissue. Markets for sperm, egg, blood, specific cells, 
cell lines and whole organs represent a much larger physical and financial portion of the 
transactions that take place on a day to day basis (Andrews and Nelkin, 2001; Lewis, 2004). Our 
focus is on general and disease-specific collections related to the expected outcomes of the Human 
Genome Project. Unlike, for example, the US, the genetics research in the Nordic countries has 
mainly been driven and led by the public sector and there is considerable political interest in the 
translation of these resources into financial, medical and academic returns, to justify public 
expenditures (cf. Tripp and Grueber, 2011). Finland has traditionally been understood as a Nordic 
welfare state, where healthcare and research have been seen to belong to the public sector. During 
the past 20 years, however, Finnish politics – like that of many other countries – has sought to seek 
new avenues through which public services and resources can be made more productive (Allardt, 
1998; Häyrinen-Alestalo and Peltola, 2006). The market-orientation of biobanking activities in 
Finland can be attributed to the rise of innovation policy thinking in Finland at the turn of the 
millennium, which also led to changes in the roles that public universities were seen to have 
(Häyrinen-Alestalo and Peltola, 2006).
A recent example of the market-oriented approach adopted within Finnish policy-making has been 
the Finnish Genome Strategy (Ministry of Social Affairs and Health, 2015), followed by a roadmap 
for Health Sector Research and Innovation (Ministry of Employment and Economy, 2016). 
According to the Genome Strategy there is a need ‘to ensure that Finland becomes an attractive 
country for top level international research and innovation utilizing genomic data’ (Ministry of 
Social Affairs and Health, 2015: 15). Among the key advantages of Finland, it is stated in the 
strategy, is that ‘Finns are genetically relatively homogenous’ which plays a key role in identifying 
‘genetic mechanisms targeted by drugs … in a manner that is difficult, if not impossible, elsewhere’
(Ministry of Social Affairs and Health, 2015: 13). 
Another example of how the Finnish innovation environment is framed and marketed as a potential 
source of interest comes from SITRA, an independent innovation fund, which has developed a 
series of PowerPoint slides widely used by the stakeholders (policy makers and researchers alike) to
market Finland. In the slide series, SITRA (2015) highlights Finland’s possibilities as a ‘testbed for 
[the] next generation of research and medical innovation’. In these slides, the genetically isolated 
population is named as a competitive factor and a cost-efficiency for investors in Finnish research. 
Moreover, as Tarkkala et al (2018) argue, the growing role of the Ministry of Employment and 
Economy in the development of the Finnish health sector shows how scientific endeavors are 
increasingly connected to expectations of economic interest. This type of interest and industry 
collaboration is exemplified in a recent announcement of FinnGen (2018) – a research project that 
aims to analyze biobank samples from 500 000 Finnish donors in order to utilize the ‘unique gene 
pool to find the next breakthroughs in disease prevention, diagnosis and treatment’ and to ‘create a 
co-operation model between public sector and healthcare industry’ eventually benefitting ‘citizens, 
businesses, biobanks and research – and ultimately the entire world’. 
The scientific study of the population and attracting outside investment and interest have tended to 
go hand-in-hand. This line of thinking and imaginary has been best exemplified by the writings of 
two of Finland's best-known geneticists and proponents of Finnish genetic homogeneity:
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The information produced from the analysis of the material would most likely have a great 
impact on the national economy. The achieved results could create the opportunity to utilize 
funds invested into the Finnish healthcare system to commercializing the new knowledge 
and even offer the possibility to partially finance the healthcare system of tomorrow. 
(Palotie and Peltonen-Palotie, 2004: 1712, authors’ translation)
The idea that collecting samples from the population would reap benefits to partially finance the 
Finnish welfare state in the future is indicative of how market thinking has penetrated scientific 
discourses of Finnish genetics. Large-scale Finnish biobanks founded in the 2010’s operate mainly 
in connection with publicly funded clinical hospitals, with the aim of benefitting future patients 
through today’s public-private partnerships, such as collaborations with international 
pharmaceutical companies (Tarkkala et al., 2018). 
 
DNA™ at the edge of the inhabitable world
 
Benjamin (2009: 353) has argued that nation states and their efforts to brand DNA should be 
‘understood as a strategic calibration’ of population classifications ‘as socio-political or biological 
entities – whose value is constantly mediated in the context of specific scientific, political, and 
economic institutions’. Examples of this ‘strategic’ calibration can be seen, for example, in the 
Genetic Map of Europe (Lao et al., 2008), where countries, such as Finland, have sought to show 
their genetic uniqueness through visual technologies of difference. The generation of these 
differences, however, requires a process in which researchers select specific individuals or 
subpopulations to serve as genetic representatives (Tupasela and Tamminen, 2015; Tupasela, 2016).
 
Among Finnish scientists, the discussion surrounding uniqueness can be found in the leveraging of 
founder populations and population isolates as exemplars of unique populations, which can be used 
to identify disease-causing variants effectively. Peltonen et al. (1999: 1913) state, for example: 
‘Finland, located at the edge of the inhabitable world, is one of the best-studied genetic isolates. The
characteristic features of population isolates – founder effect, genetic drift and isolation – have, over
the centuries, shaped the gene pool of the Finns.’ This perspective of the uniqueness, together with 
the benefits it could offer to study disease has been reinforced within contemporary Finnish 
discourse on the usefulness of Finns in biomedical research. It seeks to position Finns as a unique 
isolate, while at the same time being able to speak to the broader global questions being studied 
among geneticists. 
But where did the discourse of a homogenic and unique Finnish population come from? The effects 
of population isolates and founder effects on rare genetic diseases gave rise to what is known as 
Finnish Disease Heritage (FDH), which is a group of 36 rare Mendelian, mostly recessive, disorders
that are over-represented in the Finnish population (Nevanlinna, 1972; Norio, 2000; Norio et al., 
1973). The Finnish population has an increased frequency of rare and uncommon variants that are 
almost absent in other European populations (Kurki et al., 2014: 2). The early work done on 
monogenetic rare diseases in Finland between 1960s and early 1990s was related to the forming of 
population history and the narrative of genetic uniqueness. The history of migration related to 
founder populations was also assumed to reflect the isolation of the rest of the population when it 
came time to study more complex diseases. The so-called Finnish homogeneity, however, has 
required that specific forms of exclusion and inclusion be practiced in the sampling conducted in 
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these studies. The exclusion of people whose grandparents came from different villages, the 
exclusion of specific minorities, such as the Samì and Roma,3 and the exclusion of more recent 
arrivals from Somalia and Russia, have helped to generate, in part, a genetically homogenous image
of the population. On the other hand, individuals who married within the same village, as well as 
those descended from population isolates became representatives of Finnishness at the genetic level.
As in Mexico (Anaya-Munoz et al., 2017), the Finnish population has been studied using different 
sampling strategies and statistical methods. Studies on Mexican populations have drawn on two 
approaches; the first strategy ‘unpacks fine-grained genetic variation – favoring precision and 
realism’, while ‘the latter tends to flatten individual differences and historical depth in lieu of 
generalization’. Indeed, the first approach ‘incorporates multiple disciplinary resources into 
sampling design and interpretation’, while the second ‘privileges pragmatic considerations over 
more robust multidisciplinary analysis’ (Anaya-Munoz et al., 2017: 89). Similarly, in Finland, the 
work on FDH and monogenetic diseases simultaneously produced a population history that 
highlighted uniqueness and isolation (Tupasela, 2016). Others, however, have highlighted the 
differences and subpopulations of the country. For example, Lahermo et al. (1996) show the 
differences between the Finnish Saami population and ‘the Finns’, while Lappalainen et al. (2006: 
207) studied Y-chromosomal markers and showed that ‘the western and eastern parts of the country
have been subject to partly different population histories, which is also supported by earlier 
archaeological, historical and genetic data’. They go on to argue that it is important to incorporate 
‘Y-chromosomal data to reveal the population substructure that is often left undetected in 
mitochondrial DNA variation’. From this methodology they conclude that the ‘early assumptions of
the homogeneity of the isolated Finnish population have now proven to be false, which may also 
have implications for future association studies’ (Lappalainen et al., 2006: 207). As a matter of fact,
Lappalainen et al. (2006: 214) suggest in their paper that even the homogeneity of the maternal 
mitochondrial DNA among Finns might prove to be false once the regional differences in 
mitochondrial DNA are thoroughly studied.4 Another paper by overlapping authors ‘warn[s] against
a priori assumptions of homogeneity among Finns or other seemingly isolated populations’ 
(Salmela et al., 2008: e3519). 
 
Such criticisms, however, have not lessened claims of Finnish homogeneity. A number of other 
examples can be found in scientific texts discussing homogenous and heterogeneous populations as 
the best approach to study disease-causing variants. Varilo and Peltonen (2004: 316) have argued 
about the benefits of studying population isolates using new sequencing technologies: ‘These new 
prospects have highlighted once again the question of the best study samples for the complex gene-
mapping efforts, isolates versus more heterogeneous populations and families vs case-control 
samples.’ This line of argumentation can be found in numerous later articles. Lim et al. (2014: 2), 
for example, note that their study ‘articulates substantial advantages for studying the rare variation 
in complex phenotypes in founder populations like the Finns and by combining a unique population
genetic history with data from large population cohorts and centralized access to national health 
registers’ (emphasis added). Kurki et al. (2014: 1) argue that their study ‘illustrates the utility of 
population isolates, familial enrichment, dense genotype imputation and alternate phenotyping in 
search for variants associated with complex diseases’. Similarly, others have argued that population 
isolates, such as those found in Finland, offer ‘an exciting opportunity to identify rare and low-
frequency variants associated with complex diseases’ (Chheda et al., 2017: 477). Indeed, Wang et 
al. (2014) argue in their study that the ‘power of rare-variant association tests is higher in the 
Finnish population’. 
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This line of argumentation can be seen as a way of strategically aligning sample collections (and 
thus populations) with efforts to leverage scientific expertise and research resources into 
international research markets. In the following, we highlight the challenges and difficulties that 
researchers have in balancing the arguments of uniqueness with those of validity and 
generalizability in other populations. This is the key tension: The population must remain 
generalizable enough to attract international partners, while remaining unique enough to confer a 
competitive advantage in terms of finding disease-causing genes with small sample sizes. 
 
The difficulties of defining populations
 
Defining population boundaries among human groups poses several challenges for geneticists. In 
our interviews it was apparent that despite the strong national narrative of uniqueness, geneticists 
were very aware of the difficulty of defining population boundaries and their meaningfulness from a
biological, let alone a clinical perspective. In one interview that we conducted, a geneticist 
explained:
 
The biological definition of a population does not work very well with humans. It is 
spoken of as a type of nation-state-ethnic group, ethnic group is perhaps much closer to it. 
Our use of the term is also not always consistent, so if I started to think about Finnish 
populations then I would perhaps group Finnish-Swedes as some type of sub-population, 
as well as East and West Finns separately. But then we also use ‘Finnish population’ as an 
umbrella term under which there is all types of diversity. So in human genetics I don’t 
think there is a consistent definition which would have criteria, so it is used differently 
depending on the situation. (interview with geneticist, 2011)
 
The concern over consistency regarding the definition of a population is a challenge for genetics in 
general, since geneticists may draw on differing criteria of exclusion and inclusion for particular 
study populations (cf. Montoya, 2011: 47). In Finland, this has also been the case since researchers 
‘construct’ (Tupasela et al., 2015) populations to meet their research needs (see Montoya, 2011: 162
for a discussion on ‘population labelling’). This process invariably leads to reified notions of which 
genetic characteristics become aligned with certain groups of people, as well as those living within 
a particular nation-state. Indeed, the process gives rise to the definition of what those very groups 
are. The notion of diversity in this sense can take on multiple meanings and ends up being a relative
term through which geneticists can position their study populations in relation to others. As another 
geneticist noted in an interview:
 
I would not use the term ‘homogeneous’. I would say that in Finland there is little genetic 
diversity. Because I know that Sally used the term homogeneity to mean little diversity. 
They are not the same thing because homogeneity means that it is the same all over and 
that is not entirely true in Finland. (interview with geneticist, 2012)
 
The way that this geneticist uses the terms, it is possible to have a population which has less genetic
diversity, but at the same time cannot be considered to be homogeneous. This can be explained, for 
example, that a given population may have little genetic diversity, but the diversity that it does have
reflect clear genetic differences among those found. The researcher pointed out in the interview that
both Finns and Icelanders could be considered homogeneous, but that Finns have less genetic 
diversity, which, according to them, makes for a better population to identify disease-causing 
variants. The use of the term ‘homogeneity’ to mean both being same all over and having little 
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diversity has significance for leveraging research populations in international research markets. 
Homogeneity is a problem for extrapolating and relating one research population to others, while 
little diversity means that there is less genetic ‘noise’ for which the researchers need to account to 
find significance. In interviews, Finnish geneticists used ‘genetic homogeneity’ and ‘uniqueness’, 
although the latter could also allow for heterogeneity and be drawing attention to another 
characteristic among populations.
 
A challenge that arises from discussions about genetic uniqueness and how it is constructed derives 
from the reference populations that researchers use:
 
[I]n part, the uniqueness (‘omintakeisuus’) is the result of not using reference populations 
from the East in our studies. (interview with molecular geneticist, 2016)
 
Reference populations play a significant role in the construction of similarity and difference 
among individuals and populations and thus play an important role in notions of Finnish 
homogeneity. They serve as baselines against which other genetic samples are compared. The 
decisions associated with inclusion and exclusion in reference populations, as well as about 
which reference populations are used, can lead to the over- or under-emphasis of similarity 
and difference among populations. Following Hey’s (2015) discussion on the ‘robustness’ of 
concordant evidence, the selection of reference populations allows for similarity and 
difference to be generated methodologically. Salmela et al. (2008), for example, have noted 
that in their analysis ‘the Finnish-Swedes stood out from the rest of Western Finland only 
when Sweden was included in the analysis, which highlights the importance of relevant 
reference populations also when detecting patterns of variation within a country’. 
Different reference populations will generate different types of similarities and differences 
(for a discussion on fixing standards of reference see also M’charek, 2005: 86). Choosing one 
reference population over another will help to align similarity and difference among different 
lines of preference. For Finnish research, this has more often than not led to an alignment 
along ‘European’ genetic ancestry, as opposed to Russian and Baltic ancestry. This can be 
explained in part by the exclusion of reference populations from Russian and Baltic areas. In 
many ways, this has led to the construction of the idea that Finns are an outlier in Europe – 
which sounds odd, given the interest that Finnish researchers have had in aligning themselves 
with European ancestry. As one geneticist noted:
 
I think that regardless of reference population Finns are genuinely some type of outliers. 
Not so much as it appears in these publications, because there are bridges from the Baltics
and I’m sure we will find other outliers. For example, the Samì have not had their whole 
genome studied, but I am sure they are much further away. (interview with a geneticist, 
2015)
 
As a concept, the notion of outlier is a somewhat ambiguous. It suggests isolation and purity, 
despite the rough consensus that there are no ‘pure’ populations (see Gibbons, 2017). Yet the 
interview excerpt above is significant in that it shows how being stable or ‘genuine’ must always be
connected with or ‘bridged’ to somewhere else in order to find a rootedness or ‘tethering’ 
(Hinterberger and Porter, 2015). The relationship between being an outlier and having bridges to 
other populations is at the core of the difficulty in generating genetic uniqueness while maintaining 
similarity and significance for other research populations.
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In the following section, we will move our attention to looking at the ways in which ‘outliers’ or 
population isolates are positioned and used to attract research collaborations.
Isolates as a shortcut to success
 
The challenge with heterogeneous populations, according to some, is that in order to identify 
significant mutations or other ‘signals’ one needs a large number of samples with good clinical data 
on the patients. This is both expensive and difficult to achieve. Countries like Finland and Iceland 
claim a competitive advantage because of their populations with relatively little genetic diversity, as
well as good clinical records. A person working in a biobank described the benefits of a small and 
homogenous population in the following way:
 
In this kind of population, which is homogeneous with big enough N, the relative signal 
noise is much more beneficial. So even the smaller, rarer genetic changes, which are then 
causing a certain phenotype, we can observe them in Finnish population a) with 
considerably smaller group of those needing to be studied, which means number of 
genotyped people, than in many other or almost all other populations. And even that b) 
we do get a signal at all. That you can see the signal from the noise in the first place. And
then it is statistics to count how these relations go and if you hunt for rare enough 
variations, then you do not see them in some typical European populations but you have 
to come to Iceland or Finland …. (interview with a biobank expert, 2016)
 
What many researchers see as a shortcut to success and was aptly described in one of our interviews
by a geneticist, who highlighted the role of long linkage disequilibrium (LD)5 in providing efficacy 
when used in a meaningful way in a specific population. LD refers to ‘the nonrandom association of
alleles at two or more loci’ (Slatkin, 2008: 477). This is said to help not only in understanding ‘past 
evolutionary and demographic events’ but also ‘to map genes that are associated with quantitative 
characters and inherited diseases, and to understand the joint evolution of linked sets of genes’.
 
The linkage disequilibrium … is often not beneficial when it is long. It reduces the 
variation and then it is harder to find the causative gene. But you can fight against this 
with these rare variants that have concentrated in Finland. And if we can find these 
broken genes from the locus … if we can show that these people have for instance this 
disease, then it is sort of a shortcut to success. (interview with a geneticist, 2016)
 
Researchers also described linkage disequilibrium in relation to the competitive advantage that 
unique populations have in relation to heterogeneous populations, when used right. As one 
researcher framed the issue in concrete terms: 
 
We had 68 patients and 136 controls for the genome wide SNP analysis, which helped 
identify the gene. If you took an American or British study population, where the 
background of people may be from all over the world, then the genetic variability is so 
great that you could not do this with the small sample sizes that we use here. And that is 
the advantage that we have had that you can do the analysis, which have been expensive 
with a smaller number of samples. (Interview with a geneticist, 2012)
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To highlight the advantages of one population requires the ability to draw distinctions between 
other possible competitors. As we have mentioned, there are examples from around the world in 
which homogeneity is claimed to be a strength for attracting research interest. Iceland has one such 
population, which some researchers consider to be relatively homogeneous and for which there are 
excellent clinical records. Finns argue for a significant advantage of the Finnish population over 
that of Iceland: size. In addition to being homogeneous (in the sense of having low diversity) and 
having good clinical records, the Finnish population of 5.5 million is much larger than that of 
Iceland’s, which is slightly over 320 000. From a statistical perspective, researchers in Finland 
claim this to be a competitive advantage, in that they are able to draw on a much larger 
homogeneous population. In one of our interviews, a biobank expert described this benefit:
 
Yes, the homogeneity, the level of similarity in genome connected to a relatively big 
population, big N, it is a combination you do not have in the same way in other places. 
There are smaller populations, which are on my opinion still, like Kuusamo [a small town
in the North of Finland known to have a small founder population] is then a truly 
exceptional case, but like … hundreds of thousands, let’s say like Icelanders, to some 
extent they might be more homogeneous as a group but there are only some hundreds of 
thousands of them. We have some millions who are – perhaps not as homogeneous – but 
almost as homogeneous. (Interview with a biobank expert, 2016)
Homogeneity and isolation emerge as negotiated and relative categories when speaking to 
geneticists and experts. In our interviews, Finnish geneticists always discussed notions of 
homogeneity (or variation) and isolates in relation to others. For example, Kuusamo, a region in 
Northern Finland, which geneticists consider an isolate based on a founder population of 34 
families and low level of migration, is differentiated from the Finnish population, which was also 
discussed as a type of macro-isolate (i.e. Zara, 2015: 110). Finnish geneticists see both as types of 
isolates or outliers, but they are isolates and outliers in relation to a specific research task and 
interest. The Kuusamo population cannot perform the same utility and function that a national 
isolate can. Similarly, Iceland, which geneticists also consider a homogeneous population and a 
type of macro-isolate, was seen to have some benefits, but not others (such as a large N). Therefore,
different populations begin to take on a type of specific research function, which is then ‘marketed’ 
to international research markets for specific research purposes. Additionally, researchers using the 
Finnish population isolate as a marketing strategy want to meet the requirements of being able to 
provide a ‘big N’. The number of samples and data to which researchers have access is crucial to 
negotiating uniqueness; a homogeneous population is not too small, not too homogeneous, and not 
too odd. 
 
Confirming usability of population isolates: Replicability and its consequences for uniqueness
 
In a public lecture on biobanking, the head of Helsinki Biobank, Kimmo Pitkänen, described 
Finland as an excellent environment in which to advance personalized medicine. He identified the 
Finnish population and its genetic heritage as a strength, but he presented this strength in terms of a 
balance between being different and yet not too different: He presented Finns as ‘European’ but 
‘different than other Europeans’ (also Palotie, 2017). According to Pitkänen:
 
Finns are an interesting population in terms of our genetic characteristics, that is our 
genome, in that sense that we are among ourselves reasonably similar and a bit different 
than other Europeans or nations, even in the world, which means that here in the Finnish 
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environment we can identify those genetic differences that are behind certain diseases … 
much better than in other populations. We sort of have a lot less noise here. (Pitkänen, 
2016)
 
In most international scientific genetic research articles, for editors to accept the publication the 
research group has had to find another population in which it can replicate its result (cf. Ioannidis et
al., 2001). In studies using population isolates, there is a risk of finding a genetic risk factor that is 
unique to the population. How do you sell an important risk factor to the international scientific 
community when it cannot be shown to have the same effect anywhere else? This is the dilemma 
for many researchers and biobanks working with unique populations, and which researchers raised 
as a problem in our interviews.6 As one Finnish researcher noted in an interview:
 
Actually, we think that for marketing purposes you should not highlight that we are 
complete freaks. We should say that we have these certain strengths that make this and 
that possible, but it needs to be validated in some other population then as well. Because 
it turns a bit in the direction that if you find a marker in this odd population, then … who
cares? Like big pharma, globally … But instead it is just the route to the verification in a
larger population. (interview with a biobank expert, 2016)
 
The perspective of balancing between uniqueness and general usability elsewhere was confirmed in 
a number of informal discussions that Tarkkala had during her fieldwork. As one biobank manager 
noted in discussions related to their collections:
 
We have to say to our potential customers and collaborators that we are not that unique! 
(fieldnotes, discussion with a biobank expert, 2015) 
 
The success stories of usability do not work for everyone. Many researchers globally are not 
interested in the so-called Finnish ‘uniqueness’ in terms of genes or genomes. Some collaborators 
or potential customers might think that Finnish samples are not useful for them because they are too
odd or too homogeneous. If researchers studying large prospective cohorts want to find 
collaborators and partners and show that their collections are usable, they have to be able to 
convince others that their samples produce replicable results, and so in some cases the biobank 
operators have to start by contesting the uniqueness of their collections in terms of genetic heritage. 
Consequently, they emphasize other benefits instead, such as good clinical records that also help in 
stratifying the populations for the given research setting (Tarkkala et al., 2018). 
 
The relationship between unique populations and replication also raises another challenge for the 
discourse of unique populations. Once researchers are able to replicate a specific result in another 
population, what is the uniqueness of the original population? If researchers are able to replicate a 
particular genetic trait or marker, then the uniqueness aspect of the original populations comes into 
question. The Finnish population remains unique only as long as it is Finnish. Issues about the 
replication of findings in other populations also raise questions about which populations are the 
right ones to use for replication studies and what standards of uniqueness and generalizability are 
being generated through such processes.
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Another example of this balancing act can be found in an interview on the Finnish public 
broadcasting channel YLE, which was discussing Finnish biobanks and their strengths. The 
journalist asks from a biobank expert Anu Jalanko:
 
Leena Mattila: We [Finns] are a genetically unique population. So what kind of 
specialties can one find in the gene banks here? 
 
Anu Jalanko: Our materials are often selected to international research projects. We have 
this Finnish genetic background of ours, it has less variation and it has been considered 
that it could be easier to find these common diseases related gene variants from our 
materials because our heterogeneity is not so substantial. We do not have proper 
examples yet, but we do think that one can find the so called rare variants from our 
materials when research on diseases is done and in this way we might be able to find 
people who are healthy despite the fact that they have genetic risks or lifestyle risks and 
these rare variant persons can then be used as models when for example a medicine is 
under study. (Mattila, 2015) 
 
In the following example, a prominent Finnish researcher, who also promotes Finnish collections 
abroad, presents in a public lecture the case of loss-of-function variants, which are relatively 
frequent in the Finnish population. He confirms the reasoning based on isolation around ‘special 
kinds of genes’, and he describes the loss-of-function genes as ‘protective’. In the research 
literature, it has been stated that loss-of-function mutations ‘in genes encoding drug targets can 
provide a unique insight into the potential efficacy and safety of therapeutic modulation using that 
drug’ (Stitziel and Kathiresan, n.d.).
Not all genes are risk genes, some of them are protective, some of them protect from 
certain diseases and now it happens to be so that based on our isolation the amount of 
such genes has increased in our population that are very … that can be searched for 
from that point of view that they are protective genes. And then they are of great 
importance for drug development. So the basic idea is that if we have some gene 
whose function is completely shut down and it protects us from, for instance, heart and
coronary/vascular diseases, then it could be a good target for drug development. 
(Palotie, 2017) 
 
These kinds of arguments about the usability of population isolates reinforce some lines of research 
done in Finland. Not only do researchers bring their own research area and its scientific significance
to the foreground, but they also help build a market for Finnish biobanks internationally.
 
Conclusions: Negotiating uniqueness
 
We have argued that designating populations as unique or homogeneous has consequences for the 
‘marketability’ and usefulness of collections in international collaboration. So-called homogeneous 
populations or population isolates may allow for easier identification of possible disease-causing 
genes, but may be difficult to replicate in other populations. In the Finnish case, the construction of 
homogeneity through selective sampling leads to balancing between potential weaknesses and 
strengths. Finnish researchers have had problems publishing certain results, because they could not 
find a population in which their findings could be replicated. Drawing on notions of uniqueness and
homogeneity, then, can be counterproductive for some population studies. 
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Researchers use the term homogeneity differently to refer to different population characteristics. 
Some researchers use the term to signify ethnic homogeneity (cf. Pehkonen et al., 2017), while 
others use it to signify reduced genetic variability. Reduced genetic variability, however, may still 
allow the population to contain substantially different sub-populations. Both homogeneity and 
reduced genetic variability, however, are used as arguments that populations can support quick and 
inexpensive routes to identifying disease-causing genes, which researchers can then verify in 
heterogeneous populations. Researchers also negotiate uniqueness as a factor of relative small 
population sizes, noting that Finland is a relatively large population isolate, making it more useful 
and applicable than are smaller populations. Uniqueness also comes to carry other meanings, 
including having good and comprehensive clinical records. 
Researchers in Finland are constantly trying to show difference, while claiming enough similarity to
fit in with international research collaborations and consortiums: the branding of a population as 
unique should not make it too odd so as not to be replicable. For our informants, it was of great 
importance that their sample collections fit in with large, international data sets and cohorts. The 
consequences of this are that Finnish researchers sometimes downplay the uniqueness argument 
when similarity is a prerequisite for fitting in. Researchers working with other unique populations 
and population isolates, and seeking international collaboration, similar same challenges.
The emphasis on sampling Finnish sub-populations that have been sedentary over the centuries, and
the exclusion of ethnic minorities (particularly the Samì and Roma populations), point towards a 
valuation process in which migration and mobility are considered exclusionary criteria for genomic 
studies. The need to negotiate uniqueness in international collaborations, however, raises questions 
about the usefulness of this strategy. The strategy also contributes to the stratification of the 
population with respect to the possibilities and hopes attached to possible findings: Are those 
findings only going to be meaningful for those whose genetic lineages have been sampled and 
studied?
 
The construction (Tupasela, 2016) of unique populations can lead to distortions in the socio-
historical framing of populations, leading to different types of inclusion and exclusions, such as in 
Taiwan (Tsai, 2010: 452). Our study of Finnish researchers and biobankers shows the alignment 
work necessary to allow for unique populations to fit into large international collaborations. As 
Shim et al. (2014: 581) argue, ‘we see the fluidity of race and ethnicity and their potential 
malleability into other notions of population similarities and differences that may be as or more 
meaningful for disease etiology’. Our study has shown that population studies pose unique 
challenges in terms of replication. Findings from population studies using more heterogeneous 
populations may not be applicable or useful for so-called unique populations, while studies which 
rely on so-called unique populations may have difficulty in replicating in larger, more 
heterogeneous populations. We see this conundrum as giving rise to different forms of population 
politics within genetics research. 
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Notes
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1 The ‘All of Us Research Program’ was previously known as ‘The Precision Medicine Initiative’. The program was 
renamed during the autumn 2016. See: https://allofus.nih.gov/news-events-and-media/announcements/pmi-cohort-
program-announces-new-name-all-us-research-program
2 We transcribed and coded the interviews thematically with the help of Atlas.ti. We studied different usages of terms, 
such as population, homogeneity, heterogeneity, uniqueness, variants, competition, market, as well as different contexts 
where populations came to matter for geneticists and policy makers. These did not necessarily refer specifically to the 
Finnish population, but to the different ways that the concepts figured in the speech where significance of biobanks for 
global biomedical research was framed.
3 It should be noted, however, that the Roma culture have very specific perspectives regarding blood and have not 
traditionally been trusting towards the medical research community. It is for this reason, erhaps that theiy have not been 
used in genetic studies, while the Samì have.
4 A number of other methods have been used to study differences in the Finnish population, including single nucleotide 
polymorphisms (SNPs), copy number variant (CNV) studies, as well as more contemporary whole genome and whole 
exome studies. Regardless of the methodology used the construction of homogeneity in many Finnish studies has relied 
on sampling strategies which exclude significant portions of the population.
5Zara (2015: 108) explains how in population isolates with reduced population size due to bottleneck effects and 
subsequent ‘higher levels of inbreeding’ the LD amount increases ‘consequently modifying the haplotype pattern’. Zara
(2015: 108) continues: ‘The longer the population recovery takes after the bottleneck, the greater the effect of genetic 
drift is expected to be. During this process, common variants are rarely lost from an isolate, whereas rare variants may 
be lost or drift to higher frequencies than in the original population.’ In terms of potential for research, again, Finns as a 
population isolate have been identified as offering advantages for LD studies already 1990’s (see i.e. Hästbacka et al., 
1992: 209), which is now being reinforced as we show in this article. However, the same long LD that is said to offer 
advantage may also be a disadvantage. Thompson et al. (2010, 133) argue that even though long LD in founder or 
isolated populations ‘is expected to facilitate gene localization, extensive LD may actually limit the ability for gene 
discovery’.
6 This is not to say that replication is not important as a basic requirement in biological research. In a wider sense this 
connects with the problems of ‘false positives’ and ‘false negatives’. However, in this article we discuss the issue in 
relation to what this methodological requirement might mean when at stake are interests such as conditions that affect 
only very particular group of people. 
